CP Capital Ltd has announced plans to raise ₹25 crore through the issuance of 16,45,000 convertible warrants to its promoter group. The warrants are priced at ₹152 each. This move, aimed at capital infusion, requires shareholder approval at the EGM scheduled for November 2, 2026. The board has also proposed amending the Articles of Association to facilitate this issuance.
CP Capital Ltd Announces ₹25 Crore Preferential Warrant Issue
16,45,000 warrants to be issued at ₹152 per unit.
Total fundraise amount approximately ₹25 crore.
Reader Takeaway: Promoter-led capital infusion signals internal confidence, though dilution is expected upon future warrant conversion.
What just happened
CP Capital Ltd board approved a preferential issue of up to 16,45,000 fully convertible warrants on October 9, 2026. Each warrant carries an issue price of ₹152, comprising a ₹10 face value and a ₹142 premium. The total capital raised through this exercise will be approximately ₹25 crore. The company requires shareholder approval to proceed, which will be sought during an Extra-Ordinary General Meeting (EGM) on November 2, 2026.
Why this matters
This capital injection is directed toward the promoter and promoter group. In equity markets, such maneuvers are typically interpreted as a vote of confidence from company insiders regarding the firm's growth prospects. The funds will be deployed based on the terms stipulated, with 25% of the total amount payable at subscription and the remaining 75% due upon the exercise of conversion rights.
What changes now
To accommodate the new security type, the company is amending its Articles of Association by inserting Article 8A. This change is necessary to legally permit the issuance of convertible securities. Shareholders will vote on both this amendment and the preferential issue resolution at the upcoming EGM. The company has appointed Advocate Amit Gupta as the scrutinizer to oversee the e-voting process.
Context on Warrants
The warrants have a tenure of 18 months from the date of allotment. They are exercisable in one or more tranches, and each warrant converts into one equity share. Investors should note that the full conversion of these warrants will result in an increase in the company's equity base, which may lead to shareholding dilution for existing investors once exercised.
